Literature DB >> 17043583

Adenocarcinoma in situ of the cervix-controversies in diagnosis and treatment.

I J Etherington1, D M Luesley.   

Abstract

Adenocarcinoma in situ (AIS) of the uterine cervix is a rare condition. Pap smear screening is unsatisfactory, and the disease has no morphologic reliable colposcopic features. Diagnosis is often made by chance during the treatment of squamous pre-invasive disease, which commonly coexists with AIS. Although the entire endocervical canal can be the site of disease, most lesions lie within 1 cm of the squamocolumnar junction. Skip lesions are rare, making fertility-sparing surgery a possibility under certain conditions. Recurrent disease occurs in 14% of cases when cone margins are free of disease and rise to more than 50% if the margins are involved. The method of conization is immaterial provided a large enough specimen is taken and that the endocervical margins can be evaluated by the pathologist. Follow-up of conservatively managed women is not defined; however, we recommend that regular endocervical cytology be performed in addition to conventional cytology and colposcopy.

Entities:  

Year:  2001        PMID: 17043583     DOI: 10.1046/j.1526-0976.2001.005002094.x

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   1.925


  3 in total

1.  Cervical Cancer in Women with Normal Papanicolaou Tests: A Korean Nationwide Cohort Study.

Authors:  Miseon Kim; Hyeongsu Kim; Dong Hoon Suh; Yong Beom Kim
Journal:  Cancer Res Treat       Date:  2020-12-10       Impact factor: 4.679

2.  Significant decrease of adenocarcinoma in situ not reflected in cervical adenocarcinoma incidence in the Netherlands 1989-2003.

Authors:  H P van de Nieuwenhof; L F A G Massuger; J A de Hullu; M A P C van Ham; J A A M van Dijck; A G Siebers; R L M Bekkers
Journal:  Br J Cancer       Date:  2008-01-08       Impact factor: 7.640

3.  Results of cytology and high-risk human papillomavirus testing in females with cervical adenocarcinoma in situ.

Authors:  Sonia Andersson; Miriam Mints; Erik Wilander
Journal:  Oncol Lett       Date:  2013-05-15       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.